EMA: Documentazione sui farmaci

Lun	Mar	Mer	Gio	Ven	Sab	Dom
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Messaggio

Failed loading XML... Entity 'nbsp' not defined Entity 'nbsp' not defined Entity 'nbsp' not defined Entity 'nbsp' not defined Entity 'nbsp' not defined Entity 'nbsp' not defined

Pagina dedicata alle informazioni sui farmaci di competenza dell'EMA, relativa alle autorizzazioni e alle segnalazioni di farmacovigilanza

Warning: Undefined property: stdClass::$feedItems in /web/htdocs/www.slowpharmacy.it/home/joomla30/modules/mod_jw_srfr/helper.php on line 39

Warning: foreach() argument must be of type array|object, null given in /web/htdocs/www.slowpharmacy.it/home/joomla30/modules/mod_jw_srfr/helper.php on line 39

NUOVI FARMACI, SEGNALAZIONI EMA

Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination

Source: New medicines and opinions: human
Created on: May 15, 2025 | 10:43 am

New medicines and opinions: human | May 15, 2025 | 10:43 am
Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 28, 2025 | 09:55 am

New medicines and opinions: human | Apr 28, 2025 | 09:55 am
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:05 pm

New medicines and opinions: human | Apr 25, 2025 | 16:05 pm
Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:03 pm

New medicines and opinions: human | Apr 25, 2025 | 16:03 pm
Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm

New medicines and opinions: human | Apr 25, 2025 | 16:02 pm
Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm

New medicines and opinions: human | Apr 25, 2025 | 16:02 pm
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm

New medicines and opinions: human | Apr 25, 2025 | 16:02 pm
Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm
Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion

Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm

New medicines and opinions: human | Apr 25, 2025 | 16:00 pm

LINK esterni

Messaggio

EMA: Documentazione sui farmaci